Anemia drugs market projected to rise over nine percent CAGR by 2021, N. America and Europe to gener

Published report Global Anemia Drugs Market 2016 – 2021 says rising development of pipeline drugs combined with the growing awareness of disease in developing countries has resulted in the growth of Anemia Drugs market. Anemia Drugs has been majorly caused due to the lack of iron intake and less iron absorption mainly among pregnant women, women of reproductive age and young children.

Among the various types of anemia, market is expected to be driven by CKD anemia, due to the growing research and development towards new biosimilars such as Hypoxia-inducible factors. However, launch of late pipeline drugs such as Rivipansel and Vepoloxamer for sickle cell anemia treatment are anticipated to drive the market in forecast period.

While developed regions will continue to dominate the market in terms of revenue, emerging nations are expected to respond to the market optimistically due to the developing healthcare infrastructure and rising focus on healthcare among the growing middle class population. Global Anemia Drugs Market is forecasted to grow at a CAGR of 9.05 percent during 2016 – 2021, on account of rising incidences of anemia globally. North America region remains the major market followed by Europe in the actual period, while APAC and ROW region will witness strong growth in the forecast period.

According to research report, Global Anemia Drugs Market: Trends, Opportunities and Forecasts (2016-2021), Global Anemia Drugs market is projected to exhibit a CAGR of over ~9.05 percent during 2016 – 2021. On the basis of market segment, Global Anemia Drugs Market has been segmented by Type (Iron Deficiency Anemia, Chronic Kidney Disease related Anemia, Sickle Cell Anemia, Aplastic Anemia); By Region-North America, Europe, APAC, Latin America, MEA; By Country-USA, Canada, UK, Germany, India, Brazil, South Africa).

Report’s Strategic Recommendations are North America and Europe to Generate High Revenue, Opportunity in Rare Anemia, and Growing Inclination towards Hypoxia inducible factor (HIF) Stabilizers